Name: Latest research reports of Cohance Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Cohance Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Cohance Lifesciences Ltd.

NSE: COHANCE | BSE: 543064 | ISIN: INE03QK01018 | Industry: Pharmaceuticals
| Expensive Underperformer

615.5000 -13.60 (-2.16%)

NSE Nov 14, 2025 15:31 PM

New 52W Low today

Volume: 2.0M

Cohance Lifesciences Ltd.

29 May 2025

615.50

-2.16%

Cohance Lifesciences (BUY): To remain on a high growth trajectory

Buy: Cohance Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

4QFY25 consolidated proforma sales were 11.4% above our estimates; EBITDA/APAT was -0.4% and -5.9% below estimates

Institutional Investors have increased holdings from 18.64% to 27.33% in Sep 2025 qtr.